Ennovation Ventures

Company Profile

We focus on life science, health care, original innovation

Enran Ventures was established in 2015, focusing on venture capital companies in the fields of biomedicine and medical health. It currently manages eight equity investment funds with a management scale of more than 3 billion...

300000Million

Managed amount

65Companies

Invested companies

7Sticks

Number of funds

management team

View all team members>>

Mr. Renhai Chen

Mr. Renhai Chen

Ms. Yijia Zhang

Ms. Yijia Zhang

Mr. Jintao Deng

Mr. Jintao Deng

Portfolio

Ennovation Ventures Portfolio | Proviva Therapeutics completed more than 30 million dollar A+ round of financing, and continued to promote the clinical development of the world's first PD-1/IL-2 prodrug fusion protein.

On December 1, 2025, Proviva Therapeutics announced the completion of the A+ round o...

Ennovation Ventures Portfolio | AI Medical Company's "Null Hypothesis" won nearly 100 million yuan in Series A financing to build the China version of OpenEvidence.

The "Null Hypothesis " of AI Medical Productivity Tool Development Company recently received nearly 100 million yuan in Series A financing

Ennovation Ventures Portfolio | The 9th Medical Health Investment Excellence Awards 2025 Announcement: Ennovation Ventures Wins the "Best Investment Institution for Innovative Pharmaceuticals" Award!

On July 30, 2025, HAOYUE Capital officially released the "9th Medical and Health Investment Excellence Awards

Leads Biolabs is listed on the Hong Kong Stock Exchange today! Ennovation Ventures Capital Angel Investment has accompanied us for more than ten years, witnessing the milestone of biopharmaceuticals as the largest institutional shareholder

On July 25, 2025, China s biotechnology development history ushered in a landmark ...

Ennovation Ventures Portfolio | TransThera has landed on the Hong Kong Stock Exchange

On June 23rd, Ennovation Venturesinvested company TransThera Sciences （Nanjing）,Inc was officially listed on the

Ennovation Ventures Portfolio | Immunophage and Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University Reach a Comprehensive Strategic Cooperation on the Phase II Clinical Trial of the Globally Innovative Drug IPG7236

Recently, ImmunophagePharmaceuticals announced that it has reached a comprehensive strategic cooperation with Shanghai

Ennovation Ventures Portfolio | The First in China | Freeze-dried RSV mRNA Vaccine Approved for Clinical Trial

On December 24, 2024, the freeze-dried mRNA respiratory syncytial virus (RSV) vaccine NR2222 independently developed

Ennovation Ventures Portfolio | A Must for 190 Million Patients Globally! Hope Medicine's New Drug for Endometriosis Hits the Pain Points, with Positive Progress in Phase 2

Endometriosis is a common gynecological disease characterized by the implantation of endometrial cells outside the

Ennovation Ventures Portfolio | Hope Medicine Inc.'s Monoclonal Antibody HMI-115 Obtains the Designation of Breakthrough Therapy by CDE

Recently, Hope Medicine Inc (Hope Medicine hereinafter) announced that its new class 1 monoclonal antibody drug H

Ennovation Ventures Portfolio | InxMed Linited's Ifebemtinib: Included in the Breakthrough Therapy Category for First-line Treatment of Non-small Cell Lung Cancer; Improving the Therapeutic Window of ADC Drugs

Ifebemtinib (IN10018, BI853520) is a small molecule inhibitor targeting focal adhesion kinase (FAK) developed byInxM